A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer
- 1.3k Downloads
Current guidelines support the use of adjuvant chemotherapy (CT) following neoadjuvant chemoradiotherapy (CTRT) and surgery to treat rectal cancer, although clinical trials have provided little evidence that it is effective. We performed a systematic review of published studies to assess whether adjuvant CT improves outcome after neoadjuvant therapy and radical surgery in cases of rectal cancer.
Materials and methods
We conducted an electronic database search for randomized and nonrandomized studies in PubMed, EMBASE, Web of Science, Scopus and the Cochrane Register of Controlled Trials. We then carried out a meta-analysis by using the fixed- or random-effects models. The primary endpoint was 5-year overall survival (OS) reported as odds ratios (ORs) and 95 % confidence intervals (CIs).
Two randomized controlled trials (RCTs), one pooled analysis of five RCTs and 10 retrospective studies that included a total of 5,457 patients matched our selection criteria. Meta-analysis showed that for rectal cancer patients treated with surgery and neoadjuvant CTRT, adjuvant CT improves 5-year OS (OR, 0.64; 95 % CI, 0.46–0.88; p = 0.006) and 5-year disease-free survival (DFS) (OR, 0.71; 95 % CI, 0.6–0.83; p < 0.0001). The 5-year OS benefit was significantly larger in downstaged patients and in retrospective series. A better DFS was instead noted in all studies due to a reduced risk of local relapse.
Amongst rectal cancer patients treated with neoadjuvant therapy and surgery, adjuvant CT seems to improve the 5-year DFS and OS rates and may be discussed with patients. However, the benefit derives mainly from retrospective evidence.
KeywordsRectal cancer Adjuvant chemotherapy Overall survival Neoadjuvant chemoradiotherapy Surgery
- 1.Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C et al (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30(16):1926–1933CrossRefPubMedGoogle Scholar
- 4.Glynne-Jones R, Counsell N, Quirke P, Mortensen N, Maraveyas A, Meadows HM et al (2014) Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (Xelox) versus control. Ann Oncol 25(7):1356–1362Google Scholar
- 5.Cionini L, Sainato A, De Paoli A (2010) Final results of randomized trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer. Radiother Oncol 96(suppl 1):S113–S114Google Scholar
- 6.Breugom AJ, van den Broek CBM, van Gijn W (2013) The value of adjuvant chemotherapy in rectal cancer patients after preoperative radiotherapy or chemotherapy followed by TME-surgery: the PROCTOR/SCRIPT study. Eur J Cancer 49(suppl 3):S1Google Scholar
- 7.http://www.esmo.org/Guidelines-Practice/Clinical-Practice-Guidelines/Gastrointestinal-Cancers/Rectal-Cancer (last accessed 2014, May 1st)
- 8.http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf (last accessed 2014, May 1st)
- 12.Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1.0. The Cochrane Collaboration; 2011 [updated March 2011].Google Scholar
- 17.Valentini V, van Stiphout RG, Lammering G, Gambacorta MA, Barba MC, Bebenek M et al (2011) Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 29(23):3163–3172CrossRefPubMedGoogle Scholar
- 19.Kusters M, Valentini V, Calvo FA, Krempien R, Nieuwenhuijzen GA, Martijn H et al (2010) Results of European pooled analysis of IORT-containing multimodality treatment for locally advanced rectal cancer: adjuvant chemotherapy prevents local recurrence rather than distant metastases. Ann Oncol 21(6):1279–1284CrossRefPubMedGoogle Scholar
- 21.Valentini V, Coco C, Rizzo G, Manno A, Crucitti A, Mattana C et al (2009) Outcomes of clinical T4M0 extra-peritoneal rectal cancer treated with preoperative radiochemotherapy and surgery: a prospective evaluation of a single institutional experience. Surgery 145(5):486–494CrossRefPubMedGoogle Scholar
- 22.Collette L, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P et al (2007) Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 25(28):4379–4386CrossRefPubMedGoogle Scholar
- 23.Hildebrandt B, Rau B, Löffel J, Wust P, Nicolaou A, Gellermann J et al (2006) Adjuvant chemotherapy with folinic acid and 5-fluorouracil in patients with locally advanced rectal cancer previously treated by preoperative radiochemotherapy and curative tumor resection. Int J Color Dis 21(6):582–589CrossRefGoogle Scholar
- 27.Habr-Gama A, Gama-Rodrigues J, São Julião GP, Proscurshim I, Sabbagh C, Lynn PB et al (2014) Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys 88(4):822–828CrossRefPubMedGoogle Scholar
- 29.Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M et al (2005) Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23(34):8664–8670CrossRefPubMedGoogle Scholar
- 30.Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T et al (2014) Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol 32(22):2380–2385Google Scholar
- 31.André T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O et al (2007) Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 25(24):3732–3738CrossRefPubMedGoogle Scholar
- 34.Petrelli F, Sgroi G, Sarti E, Barni S (2013) Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg. doi: 10.1097/SLA.0000000000000368
- 35.Khrizman P, Niland JC, ter Veer A, Milne D, Bullard Dunn K, Carson WE 3rd et al (2013) Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis. J Clin Oncol 31(1):30–38CrossRefPubMedGoogle Scholar